DSFIR Stock Overview
DSM-Firmenich AG provides solutions for nutrition, health, and beauty businesses in the Switzerland, Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 1/6 |
DSM-Firmenich AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €102.70 |
52 Week High | €120.66 |
52 Week Low | €75.45 |
Beta | 0 |
1 Month Change | -3.20% |
3 Month Change | 6.87% |
1 Year Change | -13.52% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -12.79% |
Recent News & Updates
Recent updates
Shareholder Returns
DSFIR | NL Chemicals | NL Market | |
---|---|---|---|
7D | -1.3% | -1.7% | -0.1% |
1Y | -13.5% | -12.5% | 16.2% |
Return vs Industry: DSFIR underperformed the Dutch Chemicals industry which returned -12.5% over the past year.
Return vs Market: DSFIR underperformed the Dutch Market which returned 16.2% over the past year.
Price Volatility
DSFIR volatility | |
---|---|
DSFIR Average Weekly Movement | 4.5% |
Chemicals Industry Average Movement | 3.8% |
Market Average Movement | 3.6% |
10% most volatile stocks in NL Market | 7.9% |
10% least volatile stocks in NL Market | 2.2% |
Stable Share Price: DSFIR has not had significant price volatility in the past 3 months.
Volatility Over Time: DSFIR's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1902 | 28,685 | Dimitri de Vreeze | www.dsm-firmenich.com |
DSM-Firmenich AG provides solutions for nutrition, health, and beauty businesses in the Switzerland, Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. It operates through Perfumery & Beauty; Taste, Texture & Health; Health, Nutrition & Care; and Animal Nutrition & Health segments. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients.
DSM-Firmenich AG Fundamentals Summary
DSFIR fundamental statistics | |
---|---|
Market cap | €27.24b |
Earnings (TTM) | -€658.00m |
Revenue (TTM) | €10.63b |
2.6x
P/S Ratio-41.4x
P/E RatioIs DSFIR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DSFIR income statement (TTM) | |
---|---|
Revenue | €10.63b |
Cost of Revenue | €8.02b |
Gross Profit | €2.61b |
Other Expenses | €3.27b |
Earnings | -€658.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Jul 30, 2024
Earnings per share (EPS) | -2.48 |
Gross Margin | 24.57% |
Net Profit Margin | -6.19% |
Debt/Equity Ratio | 19.2% |
How did DSFIR perform over the long term?
See historical performance and comparison